HMGBI/RAGE Axis Mediates the Apoptosis, Invasion, Autophay, and Angiogenesis of the Renal Cell Carcinoma [Corrigendum]

Wu CZ, Zheng JJ, Bai YH, Xia P, Zhang HC, Guo Y. Onco Targets Ther. 2018;11:4501-4510.

Following a review of the data post-publication, the authors found the incorrect images were used for Figure 3A and 3C. The correct images for Figure 3A and 3C are shown in this corrigendum. All the correct images were collected from the second independent experimental group which formed part of the original data. The image backgrounds of this group appear different from the first independent experimental group, shown in the original article, due to the different microscopes used to collect the images (Nikon Ti-s and LEICA DMi1, respectively).

On page 4506, Figure 3A and 3C should be presented as follows:

The authors wish to explain that the analysis of all three data sets was performed prior to the photographs being taken, thus this correction has no impact on the findings of the study.

The authors apologize for this error and any confusion caused.

Wu et al **Dove**press




Figure 3 HMGBI knockdown suppressed the invasion of RCC cells.

Notes: (A) The metastatic ability of A498 cells transfected with HMGBI-shRNA, Con-shRNA, and the indicated vectors were analyzed by Matrigel invasion assays. (B) The number of A498 cells that invaded through the Matrigel-coated membrane. (C) The metastatic ability of ACHN cells transfected with HMGB1-siRNA, Con-siRNA, and the indicated vectors were analyzed by Matrigel invasion assays. (D) The number of ACHN cells that invaded through the Matrigel-coated membrane. Data are presented as mean ± SD from 3 independent experiments. *P<0.05, **P<0.01 vs Con-siRNA group; ^^P<0.01 vs sRAGE group.

Abbreviations: Con, control; HMGB1, high mobility group box 1 protein; RAGE, receptor for advanced glycation end products; RCC, renal cell carcinoma; siRNA, small interfering RNA.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S364726